Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Rt.

Egis Gyogyszergyar Zrt.

Gyula Lukacs

Balazs Volk

Maria Tothne Lauritz

Jozsef Barkoczy

Laszlo Pongo

Gyorgy Ruzsics

Gyula Simig

Tibor Szabo

Ferenc Lorant Bartha

Gyorgy Krasznai

Gyorgyi Kovanyine Lax

Eva Sipos

Balazs Havasi

Andras Boza

Tibor Mezei

Zoltan Budai

Istvan Gyertyan

Istvan Gacsalyi

Gabor Blasko

Imre Klebovich

Márta Porcs-Makkay

Andras Egyed

Eva Schmidt

Kálmán Nagy

Péter Trinka

Adrienn Keszthelyi

Ferenc Jurak

Andras Dancso

Jozsef Debreczeni

Zoltán Katona

Imre Kiraly

Imre Markovits

Lászlö Pongo

Gyula Grezal

Katalin Baloghne Nemes

Miklos Abermann

Andras Bilkei Gorzo

Balazs Peregi

Erzsebet Kaufmanne Bojti

Laszlo Jozsef Hegedus

Zsuzsanna Évinger

Maria Kovacs

Györgyi Vereczekeyné Donath

Enikö Molnar

Maria Julia Taborine Toth

Csaba Hamori

Zsolt Runge

Katalin Kataine Fadgyas

Monika Mezovari

Ede Laszlo Marvanyos

The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.

Dasatinib salts

The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The invention also relates to intermediates formed in the above process.

Process for the preparation of a rivaroxaban and intermediates formed in said process

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. 

Crystalline pharmaceutically active ingredients

The present invention relates to a process for the preparation of dabigatran etexilate of the formula 

Pharmaceutical intermediates and process for the preparation thereof

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention is related to 1-[(4-chlorophenyl)-phenylmethyl]-4-(2,2,2-trichloroethoxycarbonyl)-piperazine of the Formula (IV) and optically isomers thereof, process for preparation thereof and the use of the compound of the Formula (IV) in the preparation of 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers and salts thereof. 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers thereof are important intermediates in the preparation of non-sedating antihistamine-type active pharmaceutical ingredients. 

Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates

1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives as anxiolytic agents

Growing community of inventors

Budapest, Hungary

Gyula Lukacs